On November 20, 2015, the Government Accountability Office (GAO) released a report on costs for new Medicare Part B drugs.  The GAO found that expenditures for new Medicare Part B drugs were concentrated among a small number of drugs and conditions, and most new Part B drugs were costly for beneficiaries. The full report is available here.